Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05527717
Other study ID # RESCUE-SHOCK
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 16, 2022
Est. completion date December 31, 2028

Study information

Verified date December 2022
Source Samsung Medical Center
Contact Jeong Hoon Yang, MD
Phone 82-2-3410-3419
Email jhysmc@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, open-label, two-arm, randomized multicenter trial to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with an advanced form of CS patients who require veno-arterial extracorporeal membrane oxygenator (VA-ECMO).


Description:

Cardiogenic shock (CS) is a fatal complication of acute myocardial infarction (AMI). Until now, in this setting, it has been well-known that early revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) was associated with improved clinical outcomes although the rate of mortality remains still high in the mechanical circulatory support (MCS) era. In real-world practice, since clinically significant non-infarct related artery (non-IRA) stenosis or occlusion in addition to an IRA can be found in 70% to 80% of patients with AMI complicated by CS, the decision of revascularization strategy is a crucial issue to improve clinical outcomes in CS patients with multivessel disease. The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) and the 2017 European Society of Cardiology (ESC) guidelines recommend considering PCI of severe stenosis in non-IRA during a primary procedure to improve overall myocardial perfusion and hemodynamic stability for patients with AMI and CS. However, the CULPRIT-SHOCK trial, which is the largest randomized trial in CS, demonstrated the 30-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was higher in the immediate multi-vessel PCI than in the culprit lesion-only PCI group. In this regard, the recently updated guidelines do not recommend the routine non-IRA revascularization during primary PCI and it should be considered in selected cases in which there is a very severe flow-limiting non-IRA stenosis irrigating a large myocardial area. Nevertheless, there is still some unsolved issue regarding the role of non-IRA revascularization in AMI patients with CS. Majority of enrolled patients in the CULPRIT-SHOCK trial might have a mild form of CS (median systolic blood pressure of 100) and few patients received MCS devices (28.3% of study population). Furthermore, the mortality benefits of culprit-only PCI were attenuated at 1-year follow-up with an increased risk of repeat revascularization and hospitalization for heart failure. In contrast to the CULPRIT-SHOCK trial, the recent large United State registry from National Cardiovascular Data Registry demonstrated that the benefits of multi-vessel PCI in patients with non-ST-segment elevation MI and CS was more pronounced in those requiring MCS. In addition, recent data from the Korea Acute Myocardial Infarction National Health Registry showed that multivessel PCI was associated with a lower risk of all-cause death than culprit-only PCI, suggesting possible benefit of nonculprit lesion revascularization during the index hospitalization on long-term clinical outcomes. Therefore, the current randomized trial sought to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with advanced form of CS patients who requiring veno-arterial extracorporeal membrane oxygenator (VA-ECMO).


Recruitment information / eligibility

Status Recruiting
Enrollment 560
Est. completion date December 31, 2028
Est. primary completion date December 31, 2027
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Subject must be at least 19 years of age - Patients presented with AMI (ST-segment elevation MI [STEMI] or non-ST-segment elevation MI [NSTEMI]) complicated by CS (SCAI Shock classification C, D or E) who requiring VA-ECMO. - Target lesions amenable for planned primary PCI by operators' decision - Patients with multi-vessel disease Exclusion Criteria: - Other causes of shock (hypovolemia, sepsis, obstructive shock). - Shock due to mechanical complication to MI (rupture of papillary muscle, the ventricular septum, or free wall). - Unwitnessed out of hospital cardiac arrest with persistent Glasgow coma scale <8 after the return of spontaneous circulation. - Patients with single-vessel disease (Patients with single-vessel disease will be enrolled in the RESCUE-SHOCK registry) - Onset of shock >24 hours. - Known heparin intolerance. - Other severe concomitant disease with limited life expectancy < 6 months - Pregnancy or breast feeding - Do not resuscitate wish

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Culprit lesion only PCI
Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio. This group will be taken culprit-lesion only PCI during primary PCI.
Immediate multi-vessel PCI
Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio. This group will be taken immediate multi-vesesl PCI during primary PCI.

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rates of all-cause mortality or advanced heart failure requiring cardiac replacement therapy all-cause mortality or requiring left ventricular assisted device (LVAD) insertion or heart transplantation) 90 days after primary PCI
Secondary Rates of In-hospital mortality Death by any cause in hospital Up to 30 days
Secondary Rates of In-hospital cardiac mortality Death by cardiac cause in hospital Up to 30 days
Secondary Rates of VA-ECMO weaning success Successful weaning of VA-ECMO was defined as successful removal of VA-ECMO and not requiring further mechanical support because of recurring cardiogenic shock over the following 48 hours. Up to 30 days
Secondary Time to VA-ECMO weaning Time from VA-ECMO insertion to VA-ECMO weaning Up to 30 days
Secondary Rates of critical limb ischemia after successful VA-ECMO weaning Critical limb ischemia is defined as limb pain that occurs at rest, or impending limb loss that is caused by severe compromise of blood flow to the affected extremity. (Rutherford classification 4, 5, or 6) Up to 30 days
Secondary Cerebral Performance Category (CPC) 3-5 at discharge Neurologic performance scale at discharge Up to 30 days
Secondary Length of intensive-care unit (ICU) stay ICU stay day Up to 30 days
Secondary Total procedural time Procedural time (minutes) Immediate after the index procedure
Secondary Total amount of contrast use Contrast use (cc) Immediate after the index procedure
Secondary Rates of all-cause mortality Death by any cause 90 Days and 12 months after primary PCI
Secondary Rates of cardiac mortality Death by cardiac cause 90 Days and 12 months after primary PCI
Secondary Requirement of cardiac replacement therapy LVAD insertion or heart transplantation 90 Days and 12 months after primary PCI
Secondary Requirement of renal replacement therapy Continuous renal replacement therapy, hemodialysis, or peritoneal dialysis 90 Days and 12 months after primary PCI
Secondary Rates of myocardial infarction (MI) spontaneous MI during follow-up 90 Days and 12 months after primary PCI
Secondary Rates of MI related to culprit vessel MI related to culprit vessel during follow-up 90 Days and 12 months after primary PCI
Secondary Rates of MI related to non-culprit vessel MI related to non-culprit vessel during follow-up 90 Days and 12 months after primary PCI
Secondary Rates of stent thrombosis Academic Research Consortium (ARC)-defined definite or probable stent thrombosis 90 Days and 12 months after primary PCI
Secondary Rates of Re-hospitalization due to heart failure Re-hospitalization due to heart failure during follow-up 90 Days and 12 months after primary PCI
Secondary Rates of Re-hospitalization due to any cause Re-hospitalization due to any cause during follow-up 90 Days and 12 months after primary PCI
Secondary Rates of target-lesion revascularization (TLR) TLR during follow-up 90 Days and 12 months after primary PCI
Secondary Rates of target-vessel revascularization (TVR) TVR during follow-up 90 Days and 12 months after primary PCI
Secondary Rates of repeat revascularization Repeat revascularization during follow-up 90 Days and 12 months after primary PCI
Secondary Rates of cerebrovascular accident Cerebrovascular accident during follow-up 90 Days and 12 months after primary PCI
Secondary Rates of bleeding Bleeding ARC [BARC] type 2, 3, or 5 90 Days and 12 months after primary PCI
Secondary Rates of major bleeding (BARC type 3 or 5 90 Days and 12 months after primary PCI
See also
  Status Clinical Trial Phase
Recruiting NCT04451967 - Acute Myocardial Infarction Study in Northeastern China
Completed NCT05974397 - Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Not yet recruiting NCT04072081 - Drug-coated Balloon Versus Drug-eluting Stent in the Treatment of Coronary Artery Lesions in STEMI Patients in De Novo Coronary Lesions N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03707626 - Collateral Circulation to LAD and Wellens Sign
Completed NCT02669810 - EXCELLENT (EXpanded CELL ENdocardiac Transplantation) Phase 2
Not yet recruiting NCT04104048 - Short Term Outcome of Primary Precutaneous Coronary Intervention in Ostial Versus Non Ostial Culprit Proximal Left Anterior Descending Artery Acute Myocardial Infraction
Active, not recruiting NCT02915107 - The SORT OUT IX STEMI OCT Trial N/A
Completed NCT02896543 - The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction N/A
Completed NCT02490969 - Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19 N/A
Completed NCT02531165 - Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention N/A
Withdrawn NCT01901471 - Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock Phase 2
Completed NCT02312336 - A Pilot Study of Transcoronary Myocardial Cooling N/A
Recruiting NCT02071342 - Study of ABSORB Stent in Acute Myocardial Infarction N/A
Completed NCT02070913 - COOL-AMI EU Case Series Clinical Study
Terminated NCT01972126 - MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction N/A
Completed NCT01216995 - Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI) Phase 2
Completed NCT01887080 - Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program N/A
Withdrawn NCT01678339 - Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients N/A
Completed NCT01673893 - ClearWay Rx Readmission Registry